Monitor first-day trading volume and price action for signs of demand. The $301.5M raise provides a multi-year cash runway for pipeline development, but as a clinical-stage company with no approved products, near-term catalysts depend on clinical trial data readouts for sutacimig and HMB-002.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 1 $34.00entry
- T+1 · 7mo ago −25.47%α −25.13% · $25.34
- T+5 · 6mo ago −26.12%α −28.46% · $25.12
- T+20 · 6mo ago −20.21%α −25.47% · $27.13
- T+60 · 4mo ago +39.00%α +35.93% · $47.26
Price Chart
How similar events traded
Executive Summary
Hemab Therapeutics priced its IPO at $18.00 per share, offering 16.75M shares for gross proceeds of ~$301.5M, with an underwriter option for an additional 2.5125M shares. The stock begins trading on Nasdaq May 1, 2026 under ticker COAG. This is a dilutive event for existing holders but provides capital to advance its clinical pipeline in blood coagulation disorders.
Key Financial Metrics
Key Facts
- IPO priced at $18.00 per share for 16,750,000 shares
- Gross proceeds of approximately $301.5 million before expenses
- Underwriters have a 30-day option to purchase up to 2,512,500 additional shares
- Trading begins on Nasdaq Global Select Market on May 1, 2026 under ticker COAG
- Goldman Sachs, Jefferies, and Evercore ISI are joint book-running managers
- Offering expected to close on or about May 4, 2026
- Company is a clinical-stage biotech focused on blood coagulation disorders
Financial Impact
Gross proceeds of ~$301.5M from IPO, representing significant capital infusion for a clinical-stage biotech
Risk Factors
- Dilution for existing shareholders from the 16.75M share offering
- Clinical-stage company with no approved products or revenue
- Potential for underwriters to exercise overallotment option, adding further dilution
- Market conditions may affect post-IPO trading performance
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3285621 |
Track record
19 reports on COAG
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $38.77 Now $39.06 +0.75% settles Nov 17
- Nov 9, 20267d ago Press Release Bullish 6/10 Entry $42.81 to $39.06 Now $39.06 −8.76% ▼ −8.77% −7.08% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $49.02 to $40.86 Now $39.06 −20.32% ▼ −16.65% −19.24% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $45.09 to $39.33 Now $39.06 −13.37% ▼ −12.77% −11.86% vs SPY
- Sep 25, 20267w ago 3 Neutral 2/10 Entry $33.12 to $30.59 Now $39.06 +17.93% ▼ −7.64% −8.84% vs SPY
- Sep 17, 20268w ago Press Release Neutral 4/10 Entry $41.22 to $35.72 Now $39.06 −5.24% ▼ −13.34% −14.19% vs SPY
- Aug 11, 202613w ago 8-K Bullish 7/10 Entry $49.87 to $52.44 Now $39.06 −21.68% ▲ +5.15% +5.56% vs SPY
- Jun 17, 202621w ago Insider Buy Neutral 2/10 Entry $29.24 to $27.72 Now $39.06 +33.58% ▼ −5.20% −3.53% vs SPY
- May 21, 202625w ago Press Release Neutral 5/10 Entry $26.30 to $28.50 Now $39.06 +48.52% ▲ +8.37% +6.52% vs SPY
- May 4, 202628w ago 8-K Neutral 4/10 Entry $25.00 to $25.90 Now $39.06 +56.24% ▲ +3.60% +1.62% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers